Cancer clinical trials in the region Île-de-France

787 currently recruiting clinical trials
Region Île-de-France
Phase 2 Breast cancer #NCT06172478 #2023-507641-29-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy Hormone therapy
Excluded genetic anomalies
ALK BRAF EGFR HER2 KRAS G12C MET NTRK-1/2/3 RET ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT06172478 #2023-507641-29-00
Required histologic types
Invasive bladder cancer Upper excretory tract cancer Urethral cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2 Prostate cancer #NCT06172478 #2023-507641-29-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT06022289
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
FGFR
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Tianjin Medical University Second Hospital
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT03767075 #2024-514238-19-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
EGFR FGFR MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Institut d'oncologie du Vall d'Hebron
Phase 2 Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT07303387 #2024-519788-16-00
Cohort 1.G (Carcinome à cellules claires de l'endomètre ou de l'ovaire, de type sauvage SWI/SNF)
Required histologic types
Epithelial ovarian cancer
Required histologic sub types
Clear cell carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07303387 #2024-519788-16-00
Required disease stage
Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07303387 #2024-519788-16-00
Required disease stage
Metastatic Metastatic Castration-resistant
Required genetic anomalies
ARID1A Other mutation
Required number of previous lines of therapy for current stage of disease
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07303387 #2024-519788-16-00
Required disease stage
Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07303387 #2024-519788-16-00
Required disease stage
Metastatic Metastatic Castration-resistant
Required genetic anomalies
SMARCA4
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris